#5-20E. Unlocking Upadacitinib for Refractory IIM-ILD (Rheumatology, 2026)

What is the next therapeutic step for patients with idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD) who fail to respond to conventional immunosuppressive therapies? This episode dives into a recent retrospective study evaluating the efficacy and safety of upadacitinib in these difficult-to-treat cases. The study reveals that upadacitinib administration in refractory IIM-ILD patients led to significant improvements in pulmonary function, specifically forced vital capacity, alongside potent suppression of systemic inflammation, notably marked by a robust reduction in serum IL-6 levels. The most clinically critical takeaway from this research is its profound steroid-sparing effect; patients achieved a substantial reduction in glucocorticoid dosage, establishing upadacitinib as a highly promising, targeted treatment alternative for refractory disease. However, when critically appraising this evidence, listeners must exercise caution due to the study's single-center, retrospective design and a relatively small sample size, which may introduce selection bias and limit broad generalizability. Despite these limitations, this paper is highly relevant for practicing physicians, as it directly informs daily clinical decision-making by offering a viable rescue therapy for patients with severe, treatment-resistant IIM-ILD.

Citation: Xu Y, Peng Y, Wang Q, Zhang T, Xue J. Efficacy and safety of upadacitinib in refractory interstitial lung disease with idiopathic inflammatory myopathies: a retrospective study. Rheumatology. 2026. DOI: 10.1093/rheumatology/keag154

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.